Prognostic Effects of Imaging Ratios in Idiopathic Pulmonary Fibrosis
Investigators sought to determine a potential link between mPA/Ao ratio at diagnosis and clinical characteristics and outcomes in patients with idiopathic pulmonary fibrosis.
Restrictive Lung Disease
Idiopathic Pulmonary Fibrosis Outcomes Similar With Pneumonia or Acute Exacerbation
Based on the 2016 International Working Group (IWG) diagnostic criteria for idiopathic pulmonary fibrosis (IPF), outcomes are relatively similar between patients with IPF with pneumonia and patients with an acute IPF exacerbation.
A Tool to Assess Health in Connective Tissue Disease-Associated Interstitial Lung Disease
Researchers reviewed COPD Assessment Test results in a Japanese cohort to determine the test’s reliability and validity in patients with connective tissue disease-associated interstitial lung disease.
Progressive Skin Fibrosis in SSc Associated With Lung Function Decline
In patients with diffuse cutaneous systemic sclerosis, developing progressive skin fibrosis within 1 year is associated with a decline in lung function and worse survival.
Recombinant Human Pentraxin-2 Gets Breakthrough Tx Designation for Idiopathic Pulmonary Fibrosis
A novel treatment for idiopathic pulmonary fibrosis, PRM-151, has been granted Breakthrough Therapy designation by the FDA.
Idiopathic Pulmonary Fibrosis Prognosis Predicted by CT Parameters
Patients with idiopathic pulmonary fibrosis with better CT indices such as FEV1 and mean lung attenuation had improved outcomes.
Lung CT Helps Predict Severity, Mortality in Idiopathic Pulmonary Fibrosis
Researchers retrospectively analyzed the association among physiologic measurements, survival, and quantitative high-resolution computed tomographic indices in patients with idiopathic pulmonary fibrosis.
CT Honeycombing in Interstitial Lung Disease Linked to Higher Mortality Rates
Patients with interstitial lung disease who had honeycombing on chest computed tomography had higher mortality rates than patients without honeycombing.
Pirfenidone Slows Long-Term Progression of Idiopathic Pulmonary Fibrosis
Fewer than 25% of patients with idiopathic pulmonary fibrosis who were treated with the antifibrotic drug pirfenidone showed signs of disease progression.
Biomarkers Predictive of Systemic Sclerosis-Interstitial Lung Disease Identified
Lung‐epithelial‐derived surfactant protein has been identified as a biomarker of systemic sclerosis-interstitial lung disease.
Next post in Restrictive Lung Disease
